SCHEMBL20150525

SCHEMBL20150525

Cc1ccc2c3nn(-c4ccc([N+](=O)[O-])cc4)c(=O)c-3c[nH]c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ MAPT P10636 5/20 0.43
▸ POLB P06746 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ KAT2B Q92831 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ MMP2 P08253 1/20 0.39
▸ MMP9 P14780 1/20 0.39
▸ MMP8 P22894 1/20 0.39
▸ MMP13 P45452 1/20 0.39
▸ KHK P50053 1/20 0.39
▸ CLK1 P49759 2/20 0.39
▸ CDK5 Q00535 1/20 0.39
▸ CDK5R1 Q15078 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ PTGS2 P35354 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20150542 0.89 ALDH1A1 (0.45) NPC1RAB9AMAPTLMNAGAA
SCHEMBL538209 0.85 MIF (0.43) NPC1RAB9AMAPTLMNACLK1
SCHEMBL538458 0.84 PKM (0.46) NPC1RAB9AMAPTPOLBLMNA
SCHEMBL538073 0.84 MEN1 (0.44) NPC1RAB9AMAPTLMNAKAT2B
SCHEMBL20138058 0.84 KIF11 (0.45) NPC1RAB9AMAPTLMNACLK1
SCHEMBL7315283 0.84 NPC1 (0.54) NPC1RAB9AMAPTPOLBGAA
SCHEMBL20150506 0.84 TDO2 (0.40) NPC1RAB9APOLBLMNAKAT2B
SCHEMBL20150526 0.84 GAA (0.43) NPC1RAB9AMAPTPOLBLMNA
SCHEMBL20150523 0.84 ALDH1A1 (0.43) MAPTLMNAGAAMEN1KMT2A
SCHEMBL20150498 0.82 CDK4 (0.43) MAPTPOLBLMNAKAT2BGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180134698-A1 LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134698-A1 LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE GABRA6, HTR6, GABRD NPC1 858/4885RAB9A 1062/4885MAPT 1874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback